Table 3 Nodule outcomes based on primary malignancy.
| Primary malignancy | Total no of patients | No (%) of patients with malignant nodules | Type of malignant nodule | |||
|---|---|---|---|---|---|---|
| No (%) of patients with metastatic nodules | No (%) of patients with lung cancers | No (%) of patients with second primary cancers | No (%) of patients where primary site undetermined | |||
| Group 1 | ||||||
| Head/neck | 11 | 9 (82%) | 2 (22%) | 6 (67%) | 0 (0%) | 1 (11%) |
| Group 2 | ||||||
| Bladder | 12 | 4 (33%) | 0 (0%) | 4 (100%) | 0 (0%) | 0 (0%) |
| Breast | 64 | 16 (25%) | 10 (63%) | 5 (31%) | 1 (6%) | 0 (0%) |
| Cervix | 1 | 1 (100%) | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Oesophagus | 2 | 1 (50%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (100%) |
| Ovary | 2 | 1 (50%) | 0 (0%) | 1 (100%) | 0 (0%) | 0 (0%) |
| Prostate | 15 | 8 (53%) | 1 (13%) | 7 (89%) | 0 (0%) | 0 (0%) |
| Subtotal | 96 | 31 (32%) | 12 (39%) | 17 (55%) | 1 (3%) | 1 (3%) |
| Group 3 | ||||||
| Colon | 15 | 8 (53%) | 3 (38%) | 5 (62%) | 0 (0%) | 0 (0%) |
| Rectum | 4 | 3 (75%) | 3 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Liver | 1 | 1 (100%) | 0 (0%) | 1 (100%) | 0 (0%) | 0 (0%) |
| Carcinoid | 1 | 1 (100%) | 0 (0%) | 1 (100%) | 0 (0%) | 0 (0%) |
| Adrenal | 1 | 1 (100%) | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Kidney | 6 | 2 (33%) | 2 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Uterus | 6 | 2 (33%) | 1 (50%) | 1 (50%) | 0 (0%) | 0 (0%) |
| Subtotal | 34 | 18 (53%) | 10 (56%) | 8 (44%) | 0 (0%) | 0 (0%) |
| Group 4 | ||||||
| Thymus | 1 | 1 (100%) | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Melanoma | 8 | 4 (50%) | 1 (25%) | 2 (50%) | 1 (25%) | 0 (0%) |
| Sarcoma* | 7 | 2 (33%) | 2 (67%) | 1 (33%) | 0 (0%) | 0 (0%) |
| Testes | 4 | 1 (25%) | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Kaposi's sarcoma | 2 | 1 (50%) | 0 (0%) | 1 (100%) | 0 (0%) | 0 (0%) |
| Subtotal | 22 | 9 (41%) | 5 (50%) | 4 (40%) | 1 (10%) | 0 (0%) |
| Total*† | 151 | 64 (42%) | 28 (44%) | 32 (50%) | 2 (3%) | 2 (3%) |
*One patient with chondrosarcoma had both metastatic disease and primary lung cancer and was included in both categories.
†All tumour types were analysed individually. Because some patients had more than one primary tumour, the sum of all figures in a given column may exceed that reported as the total.